Cohance Lifesciences, Divi’s Laboratories, and SAI Life Sciences rallied after Jefferies initiated coverage with ‘Buy’ ratings, citing strong growth prospects in India’s CRDMO sector. The brokerage sees a high-teen revenue CAGR, led by China+1 diversification, pipeline visibility, and demand for diabetes and weight-loss therapies.
From 29,300 to 24,900: Nomura slashes Nifty target, says another 5% correction possible! Here’s why
Nomura has cut its Nifty target by 15% to 24,900, warning of a further 5% downside amid geopolitical tensions, rising oil prices and weakening flows.